PrognomIQ is a diagnostics company developing simple blood tests for early detection of cancer. As a spin out company from Seer, an aMoon Growth Portfolio company, PrognomiQ leverages Seer's technology for unbiased proteomic analysis at unprecedented depth, breadth, and speed.
PrognomIQ combines this unique capability for proteomic analysis with genomics and other omics data, to develop and commercialize multi-omics tests for cancer.
Location: United States, California, San Mateo
Total raised: $46M
Investors 2
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2022 | - | $46M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 12.07.2023 | Apparently Getting Smarter Makes Us Healthier: AI And Data A... | In this age of AI, various fundamental areas of our lives are being transformed. Sometimes this tran... | forbes.com... |
| 08.12.2022 | Healthcare Hires of Note | 1upHealth, a FHIR data platform and health data cloud, announced that Pieter De Leenheer has joined ... | medcitynew... |
| 15.03.2022 | PrognomiQ Raises $46M in Financing | PrognomiQ, a San Mateo, CA-based healthcare company, raised $46M in funding. The round, which bring... | finsmes.co... |
| 15.03.2022 | PrognomiQ Receives $46M Financing Round | SAN MATEO, CA, PrognomiQ today announced it has raised $46 million in financing round. >> C... | vcnewsdail... |